BTIG analyst Timothy Chiang upgraded Teva Pharma (NYSE: TEVA) from Sell to Neutral.The analyst cites the FDA approval for Ajovy.He ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE